Association of CYP1A1*2C Variant (Ile464Val Polymorphism) and Some Hematological Parameters with Acute Myeloid Leukemia (AML) and Chronic Myeloid Leukemia (CML) in Erbil-Iraq.

Sumaya Basit Abdullah, Mustafa Saber Al-Attar, Sumaya Basit
{"title":"Association of CYP1A1*2C Variant (Ile464Val Polymorphism) and Some Hematological Parameters with Acute Myeloid Leukemia (AML) and Chronic Myeloid Leukemia (CML) in Erbil-Iraq.","authors":"Sumaya Basit Abdullah, Mustafa Saber Al-Attar, Sumaya Basit","doi":"10.21271/zjpas.35.3.21","DOIUrl":null,"url":null,"abstract":"Acute Myeloid Leukemia (AML) and Chronic Myeloid Leukemia (CML) are life-threatening hematological neoplasms characterized by an uncontrolled proliferation of myeloid progenitors. The phase I metabolism response, which metabolizes xenobiotics and endogenous and exogenous DNA-reactive chemical compounds that may cause genotoxicity and raise the risk of AML and CML, is catalyzed by the cytochrome P450 (CYP) enzyme. The current study is aimed to identify the frequency of CYP1A1*2C polymorphism in AML, and CML patients. Also, compare some hematological parameters in AML and CML to determine the role of allele variants as a risk factor for developing leukemia. Blood samples were collected from 100 (50 AML and 50 CML) patients and 30 controls of both sexes at different age groups. Samples were analyzed for the prevalence of CYP1A1*2C polymorphism, and the results showed that Ile/Ile (AA)- Wild , Ile/Val (AG)- Hetero, and Val/Val (GG)- Homo mutant genotypes were not significantly elevated in the AML and CML group compared to the control group. However, statistically significant differences were found between the patient’s group concerning WBC and Hb estimation, and the frequency distribution of AA-genotypes in both AML and CML patients showed a significant difference. Despite the fact that individuals in the different genotypes have the same probability to develop AML and CML. During treatment genotypes for both AML and CML patients should be considered of patients with the GG genotype who have lower WBC and Hb, especially in AML which may increase disease severity.","PeriodicalId":23933,"journal":{"name":"ZANCO Journal of Pure and Applied Sciences","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ZANCO Journal of Pure and Applied Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21271/zjpas.35.3.21","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Acute Myeloid Leukemia (AML) and Chronic Myeloid Leukemia (CML) are life-threatening hematological neoplasms characterized by an uncontrolled proliferation of myeloid progenitors. The phase I metabolism response, which metabolizes xenobiotics and endogenous and exogenous DNA-reactive chemical compounds that may cause genotoxicity and raise the risk of AML and CML, is catalyzed by the cytochrome P450 (CYP) enzyme. The current study is aimed to identify the frequency of CYP1A1*2C polymorphism in AML, and CML patients. Also, compare some hematological parameters in AML and CML to determine the role of allele variants as a risk factor for developing leukemia. Blood samples were collected from 100 (50 AML and 50 CML) patients and 30 controls of both sexes at different age groups. Samples were analyzed for the prevalence of CYP1A1*2C polymorphism, and the results showed that Ile/Ile (AA)- Wild , Ile/Val (AG)- Hetero, and Val/Val (GG)- Homo mutant genotypes were not significantly elevated in the AML and CML group compared to the control group. However, statistically significant differences were found between the patient’s group concerning WBC and Hb estimation, and the frequency distribution of AA-genotypes in both AML and CML patients showed a significant difference. Despite the fact that individuals in the different genotypes have the same probability to develop AML and CML. During treatment genotypes for both AML and CML patients should be considered of patients with the GG genotype who have lower WBC and Hb, especially in AML which may increase disease severity.
伊拉克埃尔比勒地区CYP1A1*2C变异(Ile464Val多态性)和一些血液学参数与急性髓性白血病(AML)和慢性髓性白血病(CML)的关系
急性髓系白血病(AML)和慢性髓系白血病(CML)是危及生命的血液系统肿瘤,其特征是髓系祖细胞不受控制的增殖。I期代谢反应由细胞色素P450 (CYP)酶催化,代谢可能引起遗传毒性并增加AML和CML风险的外源性和内源性dna反应性化合物。本研究旨在确定CYP1A1*2C多态性在AML和CML患者中的频率。此外,比较AML和CML的一些血液学参数,以确定等位基因变异作为发展为白血病的危险因素的作用。从100例(50例急性髓性白血病和50例慢性髓性白血病)患者和30例不同年龄组的男女对照中采集血样。分析样本中CYP1A1*2C多态性的流行情况,结果显示,与对照组相比,AML和CML组中Ile/Ile (AA)- Wild、Ile/Val (AG)- Hetero和Val/Val (GG)- Homo突变基因型均未显著升高。然而,患者组间WBC和Hb的估计差异有统计学意义,AML和CML患者aa基因型的频率分布也有统计学意义。尽管不同基因型的个体发生AML和CML的概率相同。在治疗过程中,AML和CML患者的基因型均应考虑具有较低WBC和Hb的GG基因型患者,特别是AML患者,这可能会增加疾病严重程度。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
64
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信